Drug intelligence / Profile preview

Qixuetongzhi

Development stage: Unknown
Lead developer: Xiyuan Hospital
Administration: Oral

Overview

Qixuetongzhi is a Traditional Chinese Medicine (TCM) formula developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is primarily investigated for the treatment of stable coronary heart disease (CHD). The formula is designed to improve cardiopulmonary endurance, alleviate angina pectoris, and address comorbid anxiety and depression in CHD patients. Its therapeutic approach is rooted in TCM principles of regulating Qi and promoting blood circulation to resolve stagnation. Clinical evaluation focuses on its efficacy in improving patient prognosis and reducing long-term cardiovascular adverse events.

Brand names: Qixue Tongzhi Granule
Other names: Qixuetongzhi FormulaQixuetongzhi granule

Beyond the preview

Go deeper on Qixuetongzhi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qixuetongzhi.

Explore the full profile